Effect of Toll-like Receptor-3 Antagonist on Viral Asthma Exacerbations Via a TLR3/dsRNA Complex Pathway


Cite item

Full Text

Abstract

Background:The Toll-like receptor-3 (TLR3) ligand Poly(I:C) has been shown to induce a viral aggravation of severe asthma by identifying double-stranded RNA (dsRNA). This study aimed to evaluate the therapeutic role of the TLR3/dsRNA complex inhibitor-calbiochem compound in the treatment of Poly(I:C)-induced viral asthma exacerbations through the ovalbu-min-induced asthma model in Swiss albino mice.

Methods:Poly(I:C) and Ovalbumin drugs were injected in mice to sensitize (i.p. on 0, 7, and 14th day) and challenge (i.n. on the 21st and 22nd days). In contrast, the treatment drug TLR3/dsRNA complex inhibitor-calbiochem was given on the 21st and 22nd days intraperitoneally within the study period. In-vivo measurements were carried out in BALF and serum for pro-inflammatory cytokines, inflammatory leukocyte counts, lactate dehydrogenase (LDH) and nitrite levels, lungs/body weight index, and lung tissue histopathology using H and E staining in mice airways.

Results:High levels of cytokines (NF-κB, IL-1β, IL-5, RANTES, MIP-2, and MCP-1) are seen in groups exposed to OVA and Poly (I:C). Further, inflammatory leukocyte cell counts, lung-body weight (LW/BW) index, airway hyperresponsiveness (AHR), and lung tissue damage sug-gest exacerbations in mice airways. On the other hand, TLR3/dsRNA complex inhibitor-calbio-chem and dexamethasone significantly reversed these changes toward normal levels.

Conclusions:These results suggest that the novel compound TLR3/dsRNA complex inhibitor-calbiochem has a better therapeutic role than dexamethasone for managing inflammatory char-acteristics in asthmatic mice lungs and is a potent target for viral asthma exacerbations

About the authors

Swamita Arora

Department of Pharmacology, R.V Northland Institute of Pharmacy, U.P., 201301, India

Email: info@benthamscience.net

Kuldeep Singh

Department
of Pharmacy, Rajiv Academy for Pharmacy, Mathura, India

Email: info@benthamscience.net

Sunam Saha

Department
of Pharmacy, Rajiv Academy for Pharmacy, Mathura, India

Email: info@benthamscience.net

Shivendra Kumar

Department
of Pharmacy, Rajiv Academy for Pharmacy, Mathura, India

Author for correspondence.
Email: info@benthamscience.net

Mohammad Khalid

Department of
Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj, 11942, Saudi Arabia

Email: info@benthamscience.net

Wasim Akram

Department of Pharmacology, SPER, Jamia Hamdard University, New Delhi, 110062, India

Email: info@benthamscience.net

Sanjar Alam

Department of Pharmacology, R.V Northland Institute of Pharmacy, U.P., 201301, India

Email: info@benthamscience.net

Kantrol Kumar Sahu

Institute of Pharmaceutical Research, GLA University, Mathura,
India

Email: info@benthamscience.net

Mohit Agrawal

School of Medical and Allied
Sciences, K.R. Mangalam University, Gurugram, India

Email: info@benthamscience.net

Hema Chaudhary

School of Medical and Allied
Sciences, K.R. Mangalam University, Gurugram, India

Email: info@benthamscience.net

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Bentham Science Publishers